ArticleJCO precision oncology2026
Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2-Low Stage IV Breast Cancer: A Multicenter Retrospective Study.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HER2-Low Breast Cancer: A Review of Epidemiology, Diagnostic Challenges, Targeted Therapies, and Clinical Outcomes.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo describe and compare patient characteristics, treatment patterns, and survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)-low and HER2 immunohistochemistry 0 (IHC 0) stage IV breast cancer.
methodsA retrospective study was conducted across three academic centers in the United States. Adult patients diagnosed with stage IV breast cancer between 1-1-2010 and 12-31-2020 and classified as having either HER2-low (immunohistochemistry 1+/2+ with negative fluorescence in situ hybridization) or HER2 IHC 0 disease were followed through 12-31-2021. Patient characteristics, treatments received, and treatment discontinuation were analyzed and survival analyses were conducted using Kaplan-Meier methods.
resultsAmong 501 eligible patients, 385 were classified as HER2-low (76.8%) and 116 as HER2 IHC 0 (23.2%). No statistically significant differences were found for demographic characteristics, but
conclusionPatient characteristics were similar between HER2-low and HER2 IHC 0 subgroups except for some differences in genetic alterations. Deterioration of PFS in later lines of therapy highlights a potential unmet need. Given the high patient attrition, the most effective treatments should be used as early as indicated as some patients may not proceed to subsequent lines of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.